"RB PDAT is a revolutionary, non-invasive treatment showing remarkable promise for patients with severe infectious keratitis. This innovative therapy harnesses the power of light to combat infection ...
Early receipt of a phenotype-desirable antimicrobial therapy (PDAT), defined as beta-lactam antibiotic with the narrowest spectrum of activity that effectively targets the pathogen’s phenotype, ...
KNOXVILLE, TN, May 14, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that clinical and non-clinical data on rose bengal ...
Please provide your email address to receive an email when new articles are posted on . VisiRose, a collaboration between Provectus Biopharmaceuticals and Bascom Palmer Eye Institute, is introducing a ...
(NewsUSA) – Those who suffer from eye infections that threaten a person’s vision have a new treatment option that is noninvasive and counters the problem of antibiotic resistance, based on recent ...
KNOXVILLE, Tenn., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced a $3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results